Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview

Published:2017-05-31 Issue:6 Volume:5 Page:525-536
ISSN:2167-8707
Container-title:Expert Opinion on Orphan Drugs
language:en
Short-container-title:Expert Opinion on Orphan Drugs

Author:

Martins Diana¹,Lambrescu Ioana²,Barucca Viola³,Fazio Nicola⁴

Affiliation:

1. Endocrinology, Diabetes and Metabolism Department of Coimbra Hospital and University Centre, Coimbra, Portugal

2. Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

3. Division of Medical Oncology, Department of Oncology, Misericordia General Hospital, Grosseto, Italy

4. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of oncology, IEO, Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678707.2017.1334550

Reference83 articles.

1. Phase 3 trial of everolimus for metastatic renal cell carcinoma

2. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

3. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

4. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

5. Common toxicities of mammalian target of rapamycin inhibitors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP